Miguel Garcia-Guzman

Miguel Garcia-Guzman

Company: Rakuten Medical

Job title: Chief Scientific Officer

Seminars:

Development of ASP-1929 Illuminox, a New EGFR Targeted Therapy for the Treatment of Advanced HNSCC 12:15 pm

ASP-1929 is an anti-EGFR mAb conjugated with a small molecule, based on the Illuminox platform, that can be activated at the tumor site to induce targeted cancer cell killing Illuminox treatments can induce immunogenetic cells death and activate anti-cancer immunity ASP-1929 has been recently approved for commercialization by the PMDA in Japan to treat advanced refractory…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.